DexCom (DXCM) Tops Q4 EPS by 3c ; Offers Guidance

DexCom (NASDAQ: DXCM) reported Q4 EPS of $0.68, $0.03 better than the analyst estimate of $0.65. Revenue for the quarter came in at $1.26 billion versus the consensus estimate of $1.24 billion.

GUIDANCE:

DexCom sees FY2026 revenue of $5.16-5.25 billion, versus the consensus of $5.23 billion.

For earnings history and earnings-related data on DexCom (DXCM) click here.

You May Also Be Interested In

• Trump: nominate Heidi Overton, MD, PhD, as our next FDA commissioner
• TJX stock drops as profit outlook falls short of analyst estimates
• Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance